A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced MucosalMelanoma Who Have Previously Received Anti-PD-L1 Therapy - ARTISTRY-6
Study of ALKS 4230 in Patients with Previously Treated Advanced Melanoma
Sponsor: Alkermes, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT7271
U.S. Govt. ID: NCT04830124
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the study drug ALKS 4230 to see how well the drug works on patients with advanced cutaneous melanoma or subjects with advanced mucosal melanoma and have received prior treatment with an anti-programmed death-ligand 1 (anti-PD-L1) therapy, and your cancer has spread. This study will explore how well the drug works on your disease and body; also explore potential biomarkers by examining your blood and tissue for genes and proteins that can help identify and/or predict whether therapy would benefit someone or not.
This study is closed
Benjamin Izar, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced melanoma? Yes No
Have you received prior treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator